查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026797

臨床試驗藥物及物流市場預測至2034年－按階段、服務類型、治療領域、應用、最終使用者及地區分類的全球分析

Clinical Trial Supply & Logistics Market Forecasts to 2034 - Global Analysis By Phase, By Service Type, By Therapeutic Area, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球臨床試驗藥品和物流市場規模將達到 51.2 億美元，在預測期內以 9.5% 的複合年成長率成長，到 2034 年將達到 105 億美元。

臨床試驗藥物及物流 (CTSL) 是一個專業領域，旨在確保有效率、安全地運輸臨床研究所需的藥品、設備及其他關鍵材料。這包括庫存管理、包裝、運輸、清關和溫度控制等活動，從而確保及時將藥品送達全球各地的臨床試驗中心。 CTSL 確保臨床試驗的順利進行，並協助新藥和新療法的研發。

對臨床試驗的需求增加

不斷成長的需求正推動臨床試驗藥物及物流（CTSL）市場的快速發展。隨著臨床試驗數量的增加，安全運輸、精準庫存管理以及對溫度敏感型藥品等物料的特殊處理變得至關重要。 CTSL供應商正加強滿足這項需求，包括投資技術、拓展全球業務以及提供個人化醫療和病人參與製化解決方案。因此，蓬勃發展的臨床試驗領域正直接推動CTSL市場的成長與創新。

需要溫度控制的產品

臨床試驗通常涉及對溫度敏感的藥物、疫苗或生物檢體的運輸和儲存，這些產品需要在特定的控制條件下才能保持其療效和完整性。困難在於如何確保這些產品從生產到最終交付的整個供應鏈中始終保持在建議的溫度範圍內。任何偏離規定溫度條件的行為都可能影響臨床試驗結果的品質和可靠性，並可能導致潛在的安全問題或數據不準確。

個性化醫療的興起

隨著治療方案越來越注重個人化，針對特定患者的個人化需求也日益成長。這種模式轉移要求供應鏈必須靈活且高效，能夠滿足從獨特的藥物配方到特定患者群體等各種不同的測試需求。能夠巧妙調整供應鏈和物流策略以適應個人化醫療複雜性的公司，將能夠利用這一不斷變化的市場格局，推動創新並提高臨床試驗的成功率。

公眾的審視與關注

圍繞這些臨床試驗的負面看法和爭議可能會損害公眾信任。倫理問題、病人安全問題或被視為企業牟利的行為都可能引起媒體、監管機構和公眾的關注。社群媒體和計劃團體推動的公眾意識增強，會放大人們對供應和物流流程中缺陷的認知。負面看法可能導致監管增加、試驗進度延誤，並損害製藥公司和研究機構的聲譽，最終危及臨床試驗的整體成功，並阻礙醫學研究的進展。

新冠疫情的感染疾病：

新冠疫情對市場產生了深遠的影響，帶來了許多挑戰，例如供應鏈中斷、病患招募延遲以及特定治療領域需求激增。封鎖、旅行限制和資源重新分配影響了臨床實驗藥物的及時分發，導致物流複雜化。製藥公司和合約研究機構被迫迅速調整，凸顯了在這一前所未有的情況下，建立具有韌性的供應鏈策略和創新物流解決方案對於確保臨床試驗的連續性和效率的重要性。

在預測期內，第三階段預計將是最大的部分。

據估計，III期臨床試驗將佔據最大的市場佔有率。在臨床試驗市場中，III期臨床試驗是藥物、治療方法或治療等醫療介入措施開發和評估的關鍵階段。 III期臨床試驗被認為是複雜的臨床試驗，需要強大的技術和可靠的臨床資源，才能有效率地招募病患、快速推出試驗中心並進行經濟有效的試驗管理。此外，在III期臨床試驗中，研究人員會仔細收集數據，以驗證和擴展早期研究結果。他們的目標是證明具有統計意義的結果，並將介入措施與標準治療、安慰劑或其他相關對照組進行比較。

在預測期內，醫藥產業預計將呈現最高的複合年成長率。

在預測期內，醫藥領域預計將呈現最高的成長率。該領域專注於及時、安全地將臨床實驗藥物運送至各個臨床試驗點。高效率的供應鏈物流、溫控倉儲和合規性是關鍵因素。該市場的企業提供全面的解決方案，簡化臨床試驗藥物供應的複雜流程，從而支持新藥和療法的研發。

市佔率最大的地區：

在預測期內，北美佔據了最大的市場佔有率。北美市場的擴張受到多種因素的驅動，包括感染疾病和慢性病發病率的上升、對個人化醫療的需求以及蓬勃發展的製藥業。該地區的法規環境也十分有利，美國食品藥物管理局（FDA）在臨床試驗的核准和監管方面發揮著至關重要的作用。新冠疫情也促進了北美臨床試驗市場的成長，疫苗和治療方法的研究投入大幅增加。

複合年成長率最高的地區：

在亞太地區，由於患者數量不斷增加和治療方法價格合理，預計在預測期內將實現盈利成長。亞太地區的臨床試驗市場具有巨大的發展潛力。這主要歸功於該地區臨床試驗成本較低、生產設施不斷擴建、政府推出支持法規以及製藥公司的擴張。成本降低、大規模的目標人口、臨床試驗參與者的留存率以及監管程序的持續改進是推動該地區臨床試驗活動成長的主要因素。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球臨床試驗藥物及物流市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第6章 全球臨床試驗藥物及物流市場：依服務類型分類

  • 物流與配送
  • 儲存及儲存期
  • 包裝、標籤和遮蔽
  • 管制藥物的採購
  • 其他服務類型

第7章 全球臨床試驗藥物及物流市場：依治療領域分類

  • 腫瘤學
  • 神經病學
  • 免疫學
  • 遺傳性疾病
  • 感染疾病
  • 代謝性疾病
  • 循環系統
  • 其他治療領域

第8章：全球臨床試驗藥物及物流市場：依應用領域分類

  • 低分子化合物
  • 疫苗
  • 單株抗體
  • 細胞和基因治療
  • 其他用途

第9章：全球臨床試驗藥物及物流市場：依最終用戶分類

  • 製藥
  • 生物製藥
  • 醫療設備
  • 其他最終用戶

第10章 全球臨床試驗藥物及物流市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Parexel
  • Thermo Fisher Scientific（Patheon）
  • Catalent, Inc.
  • Packaging Coordinators Inc.
  • Almac Group
  • Piramal Pharma Solutions
  • UDG Healthcare
  • DHL
  • FedEx
  • Movianto
Product Code: SMRC24699

According to Stratistics MRC, the Global Clinical Trial Supply & Logistics Market is accounted for $5.12 billion in 2026 and is expected to reach $10.5 billion by 2034 growing at a CAGR of 9.5% during the forecast period. Clinical Trial Supply & Logistics (CTSL) is a specialized field ensuring the efficient and secure movement of medication, equipment, and other vital materials needed for clinical research. It encompasses activities like inventory management, packaging, transportation, customs clearance, and temperature control, ensuring timely delivery to clinical trial sites across the globe. CTSL ensures clinical trials run smoothly, contributing to the development of new drugs and therapies.

Market Dynamics:

Driver:

Increased demand for clinical trials

The increased demand translates to a booming Clinical Trial Supply & Logistics (CTSL) market. As more trials are conducted, the need for secure transport, precise inventory management, and specialized handling of materials like temperature-sensitive drugs becomes crucial. CTSL providers are stepping up to meet this demand by investing in technology, expanding global reach, and offering customized solutions for personalized medicine and patient engagement. Thus, the booming clinical trial landscape directly fuels the growth and innovation within the CTSL market.

Restraint:

Temperature sensitive products

Clinical trials often involve the transportation and storage of temperature-sensitive drugs, vaccines, or biological samples that require specific and controlled conditions to maintain their efficacy and integrity. The challenge lies in ensuring that these products are consistently maintained within the recommended temperature ranges throughout the supply chain, from manufacturing to final delivery. Any deviation from the specified temperature conditions can compromise the quality and reliability of the clinical trial results, leading to potential safety issues and data inaccuracies.

Opportunity:

The rise of personalized medicine

As treatments increasingly target individual patient profiles, the demand for specialized and customized pharmaceuticals escalates. This paradigm shift necessitates a flexible and efficient supply chain to accommodate diverse trial requirements, ranging from unique drug formulations to specific patient populations. Companies that adeptly adapt their supply and logistics strategies to the intricacies of personalized medicine stand to capitalize on this evolving landscape, driving innovation and enhancing clinical trial success.

Threat:

Public scrutiny and concerns

Any negative perception or controversy surrounding these trials can undermine public trust. Issues such as ethical concerns, patient safety, or perceived corporate interests may trigger intense scrutiny from the media, regulatory bodies, and the general public. Heightened public awareness, fueled by social media and advocacy groups, can amplify the impact of any perceived shortcomings in the supply and logistics processes. Negative perceptions can result in increased regulatory scrutiny, delays in trial timelines, and reputational damage for pharmaceutical companies and research organizations, thereby jeopardizing the overall success of clinical trials and hindering advancements in medical research.

Covid-19 Impact:

The Covid-19 pandemic has significantly impacted the market, introducing challenges such as disrupted supply chains, delays in patient enrollment, and increased demand for certain therapeutic areas. Lockdowns, travel restrictions, and resource reallocation have affected the timely distribution of investigational products, leading to logistical complexities. Pharmaceutical companies and contract research organizations have had to adapt rapidly, emphasizing the importance of resilient supply chain strategies and innovative logistics solutions to ensure the continuity and efficiency of clinical trials during these unprecedented times.

The Phase III segment is expected to be the largest during the forecast period

The Phase III segment is estimated to hold the largest share. The Phase 3 segment of the clinical trials market represents a crucial stage in the development and evaluation of medical interventions, such as drugs, treatments, or therapies. Phase III clinical trials are considered complex clinical trials that require both robust technologies and reliable clinical resources to recruit patients efficiently, initiate sites quickly, and provide cost-effective study management. Furthermore, during Phase 3 trials, researchers carefully gather data to confirm and extend the findings from earlier phases. They aim to demonstrate statistically significant results and compare the intervention against standard treatments, placebos, or other relevant comparators.

The pharmaceuticals segment is expected to have the highest CAGR during the forecast period

During the anticipated period, the pharmaceuticals segment is expected to increase at the most effective rate. This specialized sector focuses on ensuring the timely and secure delivery of investigational drugs to various clinical trial sites. Efficient supply chain logistics, temperature-controlled storage, and regulatory compliance are critical aspects. Companies operating in this market provide comprehensive solutions to streamline the complex process of supplying pharmaceuticals for clinical trials, supporting the development of new drugs and therapies.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The market is expanding in North America due to a number of factors, including the rising incidence of infectious and chronic diseases, the demand for personalised treatment, and the existence of a thriving pharmaceutical sector. The regulatory climate in the area is also supportive, with the FDA playing a key role in the approval and supervision of clinical trials. With an increase in vaccine and therapy studies, the COVID-19 pandemic has also fuelled growth in the North American clinical trials market.

Region with highest CAGR:

Asia-Pacific region is expected to witness profitable growth over the projection period, due to the growing patient base and affordable treatments. The clinical trials market has excellent development potential in Asia and the Pacific. This can be attributed to the region's affordable clinical trials, expanding manufacturing facilities, enacting supportive government regulations, and expanding pharmaceutical business. Cost savings, a large treatment population, participant retention in clinical trials, and ongoing regulatory procedural improvements are mostly responsible for the rise of clinical trial activities in the area.

Key players in the market

Some of the key players in Clinical Trial Supply & Logistics market include Parexel, Thermo Fisher Scientific (Patheon), Catalent, Inc., Packaging Coordinators Inc., Almac Group, Piramal Pharma Solutions, UDG Healthcare, DHL, FedEx and Movianto.

Key Developments:

In October 2023, Piramal Pharma Solutions partnered with an AI-powered platform provider to streamline clinical trial supply chain management. This partnership leverages AI and machine learning to optimize inventory management, route planning, and real-time visibility into the location and status of clinical trial supplies.

In September 2023, Thermo Fisher Scientific (Patheon) acquired a leading European clinical trial logistics company, significantly increasing presence in Europe and expertise in complex trial logistics.

In February 2023, Parexel launched a new expert series, New Medicines, Novel Insights. The series features fresh insights from the company's global, cross-functional experts analyzing drug development trends and offering evidence-based guidance to the biopharmaceutical industry.

Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Service Types Covered:

  • Logistics & Distribution
  • Storage & Retention
  • Packaging, Labeling, and Blinding
  • Comparator Sourcing
  • Other Service Types

Therapeutic Areas Covered:

  • Oncology
  • Neurology
  • Immunology
  • Genetic Diseases
  • Infectious Diseases
  • Metabolic Disorders
  • Cardiology
  • Other Therapeutic Areas

Applications Covered:

  • Small Molecules
  • Vaccine
  • Monoclonal Antibodies
  • Cell & Gene Therapy
  • Other Applications

End User Covered:

  • Pharmaceuticals
  • Biologicals
  • Medical Device
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Clinical Trial Supply & Logistics Market, By Phase

  • 5.1 Introduction
  • 5.2 Phase I
  • 5.3 Phase II
  • 5.4 Phase III
  • 5.5 Phase IV

6 Global Clinical Trial Supply & Logistics Market, By Service Type

  • 6.1 Introduction
  • 6.2 Logistics & Distribution
  • 6.3 Storage & Retention
  • 6.4 Packaging, Labeling, and Blinding
  • 6.5 Comparator Sourcing
  • 6.6 Other Service Types

7 Global Clinical Trial Supply & Logistics Market, By Therapeutic Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Neurology
  • 7.4 Immunology
  • 7.5 Genetic Diseases
  • 7.6 Infectious Diseases
  • 7.7 Metabolic Disorders
  • 7.8 Cardiology
  • 7.9 Other Therapeutic Areas

8 Global Clinical Trial Supply & Logistics Market, By Application

  • 8.1 Introduction
  • 8.2 Small Molecules
  • 8.3 Vaccine
  • 8.4 Monoclonal Antibodies
  • 8.5 Cell & Gene Therapy
  • 8.6 Other Applications

9 Global Clinical Trial Supply & Logistics Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceuticals
  • 9.3 Biologicals
  • 9.4 Medical Device
  • 9.5 Other End Users

10 Global Clinical Trial Supply & Logistics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Parexel
  • 12.2 Thermo Fisher Scientific (Patheon)
  • 12.3 Catalent, Inc.
  • 12.4 Packaging Coordinators Inc.
  • 12.5 Almac Group
  • 12.6 Piramal Pharma Solutions
  • 12.7 UDG Healthcare
  • 12.8 DHL
  • 12.9 FedEx
  • 12.10 Movianto

List of Tables

  • Table 1 Global Clinical Trial Supply & Logistics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Clinical Trial Supply & Logistics Market Outlook, By Phase (2023-2034) ($MN)
  • Table 3 Global Clinical Trial Supply & Logistics Market Outlook, By Phase I (2023-2034) ($MN)
  • Table 4 Global Clinical Trial Supply & Logistics Market Outlook, By Phase II (2023-2034) ($MN)
  • Table 5 Global Clinical Trial Supply & Logistics Market Outlook, By Phase III (2023-2034) ($MN)
  • Table 6 Global Clinical Trial Supply & Logistics Market Outlook, By Phase IV (2023-2034) ($MN)
  • Table 7 Global Clinical Trial Supply & Logistics Market Outlook, By Service Type (2023-2034) ($MN)
  • Table 8 Global Clinical Trial Supply & Logistics Market Outlook, By Logistics & Distribution (2023-2034) ($MN)
  • Table 9 Global Clinical Trial Supply & Logistics Market Outlook, By Storage & Retention (2023-2034) ($MN)
  • Table 10 Global Clinical Trial Supply & Logistics Market Outlook, By Packaging, Labeling, and Blinding (2023-2034) ($MN)
  • Table 11 Global Clinical Trial Supply & Logistics Market Outlook, By Comparator Sourcing (2023-2034) ($MN)
  • Table 12 Global Clinical Trial Supply & Logistics Market Outlook, By Other Service Types (2023-2034) ($MN)
  • Table 13 Global Clinical Trial Supply & Logistics Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 14 Global Clinical Trial Supply & Logistics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 15 Global Clinical Trial Supply & Logistics Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 16 Global Clinical Trial Supply & Logistics Market Outlook, By Immunology (2023-2034) ($MN)
  • Table 17 Global Clinical Trial Supply & Logistics Market Outlook, By Genetic Diseases (2023-2034) ($MN)
  • Table 18 Global Clinical Trial Supply & Logistics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 19 Global Clinical Trial Supply & Logistics Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 20 Global Clinical Trial Supply & Logistics Market Outlook, By Cardiology (2023-2034) ($MN)
  • Table 21 Global Clinical Trial Supply & Logistics Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
  • Table 22 Global Clinical Trial Supply & Logistics Market Outlook, By Application (2023-2034) ($MN)
  • Table 23 Global Clinical Trial Supply & Logistics Market Outlook, By Small Molecules (2023-2034) ($MN)
  • Table 24 Global Clinical Trial Supply & Logistics Market Outlook, By Vaccine (2023-2034) ($MN)
  • Table 25 Global Clinical Trial Supply & Logistics Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 26 Global Clinical Trial Supply & Logistics Market Outlook, By Cell & Gene Therapy (2023-2034) ($MN)
  • Table 27 Global Clinical Trial Supply & Logistics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 28 Global Clinical Trial Supply & Logistics Market Outlook, By End User (2023-2034) ($MN)
  • Table 29 Global Clinical Trial Supply & Logistics Market Outlook, By Pharmaceuticals (2023-2034) ($MN)
  • Table 30 Global Clinical Trial Supply & Logistics Market Outlook, By Biologicals (2023-2034) ($MN)
  • Table 31 Global Clinical Trial Supply & Logistics Market Outlook, By Medical Device (2023-2034) ($MN)
  • Table 32 Global Clinical Trial Supply & Logistics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.